Market

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peri

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peri
Read More

Related Posts

Treasury market logs worst weekly rout since April, in a bad sign for borrowers

Treasury market logs worst weekly rout since April, in ...

Alphabet CEO Pichai Sundar sells $10.3m in GOOGL stock

Alphabet CEO Pichai Sundar sells $10.3m in GOOGL stock

Carvana gets a spot in the S&P 500 ahead of these tech stocks

Carvana gets a spot in the S&P 500 ahead of these tech ...

Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares for $75,400

Raykov Rosty sells Fennec Pharmaceuticals (FENC) shares...

Enanta Pharma CBO Luu sells $19,836 in stock

Enanta Pharma CBO Luu sells $19,836 in stock

Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock

Adaptive Biotechnologies CSO Robins sells $672,515 in A...